Biomed Pharmacother. 2025 Oct:191:118440. Posterior segment diseases are a leading cause of irreversible blindness and remain challenging to treat with current therapies. Blood-derived products have emerged as promising regenerative tools due to their anti-inflammatory, neuroprotective, and regenerative properties. This review synthesizes evidence from 46 clinical studies published between 2019 and 2025, covering 1253 patients and 1570 eyes treated with platelet-rich derivatives for ocular fundus diseases. The most frequent indications were structural defects (59 %), inherited retinal dystrophies (11 %), optic neuropathies (11 %), age-related macular degeneration (7 %), and vascular dysfunctions (5 %). These therapies were administered via various routes, including intravitreal, subtenon, suprachoroidal, and subretinal injections, as well as eye drops and fibrin membranes.

Ophthalmol Ther. 2025 Sep;14(9):2253-2281. Immunosafe plasma rich in growth factors eye drops (is-ePRGF) have shown anti-inflammatory and regenerative effects on ocular surface diseases (OSD). However, medical or technical issues may preclude some patients from undergoing autologous blood extraction. We aimed to evaluate the safety and clinical outcomes of allogeneic is-ePRGF therapy for refractory OSD in real-world practice.

Cryobiology. 2025 Jun;119:105214. Long-term stability of blood-derived eye drops is required to adapt the use of this treatment to prolonged clinical treatments and more green pharmacy. This study has been designed to assess the long-term storage life of freeze-dried plasma rich in growth factors (PRGF) eye drops, maintaining their biological content and activity. Thus, blood from five healthy donors was extracted and centrifuged for obtaining PRGF. The obtained PRGF eye-drops after platelet activation were freeze-stored or were lyophilized and then stored for 18 and 24 months at room temperature (RT) or at + 5 °C. Growth factor content and proliferative potential of PRGF eye drops on primary human keratocytes (HK) was evaluated at each storage time and condition.

Int J Oral Maxillofac Surg. 2025 May 28:S0901-5027(25)00118-3. The aim of this systematic review was to comprehensively analyse recent studies on the application of artificial intelligence (AI) in dental implantology. The PRISMA guidelines were followed. Five databases were accessed: Scopus, Web of Science, MEDLINE/PubMed, IEEE Xplore, and JSTOR. Documents published between 2018 and October 15, 2024 relating to AI and implantology were considered. Exclusions encompassed reviews, opinion articles, books, conference references, studies using AI as a supplementary method, AI for teaching implant dentistry, and AI for implant fabrication, prothesis, or design. A total of 120 relevant papers were included. Risk of bias was assessed using PROBAST.

J Prosthet Dent. 2025 May;133(5):1325.e1-1325.e8. The seal at the implant-abutment connection (IAC) is crucial for ensuring implant-prosthetic function and reducing the risk of peri-implant diseases. An accurate determination of the first IAC gap under realistic dynamic-loading conditions is needed to investigate current and future IAC designs.